3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
54
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Neoplasm Metastasis
4
Sarcoma, Ewing
3
Neoplasms
3
Medulloblastoma
3
Lymphoma, Non-Hodgkin
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Astrocytoma
3
Wilms Tumor
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Osteosarcoma
2
Oligodendroglioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Lymphoma
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioblastoma
2
Ependymoma
2
Colonic Neoplasms
2
Xanthogranuloma, Juvenile
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Teratoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Interventions
Trastuzumab
3
Sugammadex
2
Neostigmine
2
Cisplatin
2
valrubicin
1
tucatinib
1
pembrolizumab
1
niraparib
1
enfortumab vedotin
1
avelumab
1
atezolizumab
1
Surveys and Questionnaires
1
Sunitinib
1
Standard of Care
1
Rocuronium
1
Pemetrexed
1
Paclitaxel
1
Nephroureterectomy
1
Neoadjuvant Therapy
1
Mitomycin
1
Lymph Node Excision
1
Glycopyrrolate
1
Gemcitabine
1
GSK-3326595
1
Fulvestrant
1
Docetaxel
1
Cetuximab
1
Afatinib
1
Administration, Intravesical
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Urologic Neoplasms
×
palbociclib
×
Clear all
No trials found.